An observational study in Relapsed and Refractory Multiple Myeloma (RRMM), sponsored by Regeneron Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by Regeneron Pharmaceuticals · Observational
Primary Objective:
Secondary Objectives:
3,632 studies on the registry are indexed under Multiple Myeloma; 744 are open to participants now.
This study's enrollment of 62 is below the median of 140 across 468 observational studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Regeneron Pharmaceuticals is the lead sponsor of 400 studies on the registry; 91 are open to participants now.
Of its 120 completed or terminated interventional studies of FDA-regulated products, 77 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with RRMM who have either at least three prior lines of therapy (LOT) and are triple-class exposed (3L+/TCE), or are triple-class refractory (TCR).
Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Real-world (RW) patients with RRMM who have either at least three prior lines of therapy (LOT) and are triple-class exposed (3L+/TCE), or are triple-class refractory (TCR), meet similar inclusion/exclusion criteria used to establish phase 2 cohort 2 of the R5458-ONC-1826 trial, and are initiating currently available therapies.
Other: Non-Interventional
No study treatment will be administered on this study.
Proportion of patients exposed to each type of regimen by line of therapy (LOT)
Distribution of treatment regimens
Time frame: Up to 6 years
Proportion of patients with objective response rate (ORR)
Defined as stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR)
Time frame: Up to 6 years
Duration of response (DOR)
Defined as time from the date of the first documented response (best overall response of sCR, CR, VGPR, PR) until the first date of progressive disease (PD) by International Myeloma Working Group (IMWG) or death due to any cause, whichever occurs first.
Time frame: Up to 6 years
Progression-free survival (PFS)
Defined as time from the start of study treatment until the first date of PD by IMWG, or death due to any cause, whichever occurs first.
Time frame: Up to 6 years
Overall survival (OS)
OS is measured from the start of study treatment until death due to any cause.
Time frame: Up to 6 years
Time to next treatment (TTNT)
Defined as time from the start of study treatment until the initiation of the subsequent LOT.
Time frame: Up to 6 years
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regeneron Pharmaceuticals